Prostate-specific antigen (PSA) screening does reduce the risk of dying from prostate cancer, according to a major new review, marking a significant shift in medical evidence after years of discouragement. However, experts emphasize that the benefit only materializes when screening is done thoughtfully, with careful follow-up and newer diagnostic tools to avoid unnecessary biopsies and overtreatment.

Does PSA Screening Actually Save Lives?

A comprehensive review by the Cochrane Collaboration, an influential international research organization, analyzed data from six large trials involving 800,000 participants across Europe and North America. The findings show "moderate certainty" that PSA screening leads to a reduction in disease-specific deaths. The benefit is modest but real: approximately two fewer prostate cancer deaths for every 1,000 men screened over time.

This represents a major reversal from the 2013 Cochrane review, which found no clear survival benefit and contributed to widespread discouragement of PSA screening. The U.S. Preventive Services Task Force (USPSTF) discouraged the test for all men starting in 2012, after initially restricting it in men 75 and older in 2008. The new evidence, which includes longer follow-up data from studies tracking men for up to 23 years, suggests PSA screening has a legitimate place in prostate cancer detection when implemented carefully.

Why Did PSA Screening Fall Out of Favor?

The concern wasn't that PSA screening doesn't work; it was that it works too well at finding cancer, including cancers that would never harm a man. PSA is a marker of prostate tissue, not cancer itself, so elevated levels can result from benign conditions like benign prostatic hyperplasia (enlarged prostate) or inflammation. This led to widespread overdiagnosis and overtreatment, with men undergoing unnecessary biopsies and aggressive treatments for slow-growing cancers they would have lived with for decades without symptoms.

Prostate biopsies carry risks of infection, and surgeries to remove tumors can cause erectile dysfunction and other serious side effects. About half of prostate cancers diagnosed in the United States don't warrant aggressive treatment and are better managed through monitoring. The challenge has always been distinguishing between cancers that need treatment and those that don't.

How Are Doctors Improving PSA Screening in 2026?

The key to making PSA screening beneficial without causing harm lies in combining it with smarter diagnostic tools. Experts now recommend an integrated approach that uses multiple technologies to refine which men actually need biopsies:

• Multiparametric MRI: Prostate magnetic resonance imaging allows doctors to visualize suspicious lesions and target biopsies to areas most likely to contain clinically significant cancer, substantially reducing the diagnosis of low-grade cancers while maintaining the ability to detect aggressive tumors.
• Biomarker Tests: Blood and urine biomarkers offer additional risk assessment after an elevated PSA test, with several commercially available assays showing high negative predictive value to identify men at low risk who can safely avoid biopsy.
• Artificial Intelligence and Radiomics: Emerging tools such as radiomics and artificial intelligence may further improve diagnostic precision and personalize early detection strategies.

"We are doing better now in selecting patients for biopsy. In the past we would biopsy anyone with just an elevated PSA, but now we have other tools to further refine who should get a biopsy: we have biomarkers in urine, we have biomarkers in blood, we have MRI imaging to facilitate biopsies, such that we are actually maximizing the detection of high-grade prostate cancer and minimizing the detection of low-grade prostate cancer," said Simpa Salami, a professor of urology at the University of Michigan.

Simpa Salami, Professor of Urology at the University of Michigan

What Does Quality PSA Screening Actually Look Like?

The new evidence doesn't endorse one-time PSA testing at health fairs or community events. Instead, experts stress that the benefits depend on ongoing medical relationships and consistent follow-up. Men who benefited from screening in the research studies didn't just get tested once; they had regular PSA tests over time and worked with their physicians to interpret results and decide on further action.

"The participants in the studies who experienced benefits didn't just get their levels tested once, they did so on a regular basis, and worked with their physicians over time to interpret the results and decide further action. It is not what is commonly done in the United States, which is getting your PSA drawn from a van parked at a state fair, a van in the parking lot of a church, or at a football party," explained Otis Brawley, a professor of oncology and epidemiology at Johns Hopkins University's Sidney Kimmel Comprehensive Cancer Center.

Otis Brawley, Professor of Oncology and Epidemiology at Johns Hopkins University

Doctors with ongoing relationships with their patients are better positioned to reduce the risk of overtreatment because they have multiple data points to decide which patients need biopsies and which don't. This continuity of care is a challenge in the American health care system but is essential for PSA screening to deliver its benefits.

How to Approach PSA Screening Conversations With Your Doctor

• Discuss Your Risk: Talk with your doctor about your personal and family history of prostate cancer, your age, and your overall health to determine whether screening is appropriate for you.
• Understand the Benefits and Risks: Know that screening can prevent some prostate cancer deaths but also carries risks of overdiagnosis and overtreatment, particularly for slow-growing cancers.
• Plan for Ongoing Monitoring: If you decide to be screened, commit to regular PSA tests and follow-up appointments with your doctor rather than one-time testing, as the research shows benefits depend on consistent medical relationships and interpretation of results over time.
• Ask About Advanced Diagnostics: If your PSA is elevated, ask your doctor whether biomarker tests or MRI imaging can help determine whether a biopsy is truly necessary before undergoing the procedure.

What About Men With Advanced Prostate Cancer?

For men already diagnosed with advanced prostate cancer, PSA levels during treatment provide important prognostic information, though they don't tell the whole story. A large analysis of 7,129 patients with metastatic or very high-risk prostate cancer found that achieving very low PSA levels (0.2 ng/mL or lower) at 24 weeks after starting hormone therapy was strongly associated with improved long-term survival.

However, disease burden remained prognostically important even among patients with similarly low PSA levels. For example, among patients achieving PSA levels of 0.2 ng/mL or lower at 24 weeks, 96-month overall survival ranged from 64.1% in those with low-volume metastatic disease to 44.6% in those with high-volume disease. This means that PSA response alone may not fully capture prognosis; the extent of cancer spread matters significantly.

The key takeaway from recent evidence is that PSA screening and monitoring have a role in prostate cancer detection and management, but success depends on thoughtful implementation. Men should have conversations with their doctors about whether screening is right for them, understand that the benefits come from consistent follow-up rather than one-time testing, and know that newer diagnostic tools can help reduce unnecessary procedures while maintaining the ability to catch aggressive cancers early.